Cite
Ahn GS, Hwang K, Kim TM, et al. Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study). Cancer Res Treat. 2021;doi: 10.4143/crt.2021.393.
Ahn, G. S., Hwang, K., Kim, T. M., Park, C. K., Chang, J. H., Jung, T. Y., Kim, J. H., Nam, D. H., Kim, S. H., Yoo, H., Hong, Y. K., Kim, E. Y., Lee, D. E., Joo, J., Kim, Y. J., Choe, G., Choi, B. S., Kang, S. G., Kim, J. H., & Kim, C. Y. (2021). Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study). Cancer research and treatment, . https://doi.org/10.4143/crt.2021.393
Ahn, Grace S, et al. "Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study)." Cancer research and treatment vol. (2021). doi: https://doi.org/10.4143/crt.2021.393
Ahn GS, Hwang K, Kim TM, Park CK, Chang JH, Jung TY, Kim JH, Nam DH, Kim SH, Yoo H, Hong YK, Kim EY, Lee DE, Joo J, Kim YJ, Choe G, Choi BS, Kang SG, Kim JH, Kim CY. Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study). Cancer Res Treat. 2021 Jul 06; doi: 10.4143/crt.2021.393. Epub 2021 Jul 06. PMID: 34237210.
Copy
Download .nbib